-
Views
-
Cite
Cite
Bernard Masquelier, Audrey Taieb, Sandrine Reigadas, Bruno Marchou, Christine Cheneau, Bruno Spire, Charlotte Charpentier, Catherine Leport, François Raffi, Geneviève Chêne, Diane Descamps, on behalf of the APROCO-COPILOTE study group, C. Leport, F. Raffi, G. Chêne, R. Salamon, J.-P. Moatti, J. Pierret, B. Spire, F. Brun-Vézinet, H. Fleury, B. Masquelier, G. Peytavin, R. Garraffo, D. Costagliola, P. Dellamonica, C. Katlama, L. Meyer, D. Salmon, A. Sobel, L. Cuzin, M. Dupon, X. Duval, V. Le Moing, B. Marchou, T. May, P. Morlat, C. Rabaud, A. Waldner-Combernoux, P. Reboud, Sandrine Couffin-Cadiergues, Lucie Marchand, V. Bouteloup, A. D. Bouhnik, C. Brunet-François, V. Caron, M. P. Carrieri, M. Courcoul, F. Couturier, L. Hardel, L. Iordache, P. Kurkdji, S. Martiren, M. Préau, C. Protopopescu, J. Surzyn, A. Taieb, V. Villes, J. L. Schmit, J. M. Chennebault, J. P. Faller, N. Mgy-Bertrand, B. Hoen , Drobachef, O. Bouchaud, M. Dupon, Longy-Boursier, P. Morlat , J. M. Ragnaud, P. Granier, M. Garré, R. Verdon, D. Merrien, A. Devidas, A. Sobel, L. Piroth, C. Perronne, E. Froguel, J. Ceccaldi, D. Peyramond, C. Allard, J. Reynes, T. May, F. Raffi, J. G. Fuzibet , P. Dellamonica, P. Arsac, E. Bouvet, F. Bricaire, P. Bergmann, J. Cabane, J. Monsonego, P. M. Girard, L. Guillevin, S. Herson, C. Leport, M. C. Meyohas, J. M. Molina, G. Pialoux , D. Salmon, P. Roblot, R. Jaussaud, C. Michelet, F. Lucht, T. Debord, D. Rey, J. P. De Jaureguiberry, B. Marchou, L. Bernard, Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy, Journal of Antimicrobial Chemotherapy, Volume 66, Issue 7, July 2011, Pages 1582–1589, https://doi.org/10.1093/jac/dkr153
Close - Share Icon Share
Abstract
The aim of our study was to determine whether HIV-1 DNA level before antiretroviral therapy (ART) was associated with short- and long-term virological and immunological responses.
Patients starting first-line protease inhibitor-containing regimens were enrolled in a prospective multicentre cohort in 1998–99. HIV-1 DNA was quantified using real-time PCR at baseline and after 1 year of ART. The association between HIV-1 DNA and virological and immunological responses after 1 and 7 years on ART was studied in multivariate regression models along with other biological and clinical variables. Virological failure (VF) at month 12 (M12) was defined as a plasma HIV-1 RNA >500 copies/mL. Time to death or two plasma HIV-1 RNA >500 copies/mL between M12 and M84 was studied for long-term VF.
HIV-1 DNA levels were measured in 148 patients. The median baseline peripheral blood mononuclear cell (PBMC) HIV-1 DNA was 3.7 log10 copies/106 PBMCs. At M12, the median PBMC HIV-1 DNA was 2.99 log10 copies/106 PBMCs. The median decrease in PBMC HIV-1 DNA between M0 and M12 was −0.7 log10 copies/106 PBMCs. Higher baseline PBMC HIV-1 DNA and plasma HIV-1 RNA were independently associated with a higher risk of VF at M12. Only the baseline plasma HIV-1 RNA was independently associated with long-term virological response. The baseline CD4 cell count was the only parameter associated with short- and long-term immunological responses.
HIV-1 DNA impacted the virological response in our cohort. Further research is warranted to study the impact of HIV-1 DNA with currently recommended first-line cART.
